[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM Jr, Clayman G, Morrison WH, Liu DD, Blumenschein G Jr, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK: Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer; 2003 Nov 15;98(10):2214-23
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
  • BACKGROUND: The objectives of this study were to determine the efficacy, organ-preservation rate, and safety of intraarterial (IA) cisplatin in combination with intravenous paclitaxel and ifosfamide in patients with locally advanced carcinoma of the paranasal sinuses who required orbital exenteration or major craniofacial resection for complete tumor resection.
  • Five of those 19 patients (26%) achieved a complete response (CR), 6 patients (32%) achieved a partial response, and 8 patients (42%) had stable disease or developed progressive disease.
  • Eye-sparing surgery followed by radiotherapy (RT) was feasible in 7 of 24 patients, RT was offered to only 7 patients, whereas 3 patients received chemotherapy and RT, 2 patients refused further therapy, 3 patients underwent craniofacial resection with orbitectomy, and 1 patient was treated systemically for metastatic disease.
  • At the completion of treatment, 14 of 23 patients (61%) with locally advanced disease were disease free, and the orbit was preserved in 21 of 24 patients (88%).
  • CONCLUSIONS: Despite the encouraging organ-preservation rate, the approach studied resulted in substantial toxicity, and more effective adjunctive therapy is needed.
  • Alternative approaches, including the integration of targeted therapy agents in induction chemotherapy regimens followed by concomitant chemotherapy and RT or eye-sparing surgery, need further exploration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Eye Enucleation. Female. Humans. Ifosfamide / administration & dosage. Infusions, Intra-Arterial. Infusions, Intravenous. Male. Middle Aged. Orbit / surgery. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14601092.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Jimbo H, Kamata S, Miura K, Asamoto S, Tada S, Endo T, Masubuchi T, Nakamura N, Fushimi C: Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo); 2010 Jan;50(1):20-6; discussion 26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases.
  • Cancers of the paranasal sinuses and nasal cavity are the most common malignant tumors of the anterior and anterolateral skull base.
  • The treatment of these tumors affecting the skull base is complex due to the significant anatomical features.
  • Using a combination of adjuvant radiation and chemotherapy, we have achieved a 2-year disease-free survival rate of 90% in these cases.
  • Here we present our recent institutional experience and treatment policy employed during the past 3 years.
  • [MeSH-major] Neurosurgical Procedures / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base / pathology. Skull Base / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Cranial Fossa, Middle / anatomy & histology. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Orbit / anatomy & histology. Orbit / pathology. Orbit / surgery. Osteotomy / contraindications. Osteotomy / methods. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Patient Care Team. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / statistics & numerical data. Reconstructive Surgical Procedures / methods. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098020.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Zagolski O, Dwivedi RC, Subramanian S, Kazi R: Non-Hodgkin's lymphoma of the sino-nasal tract in children. J Cancer Res Ther; 2010 Jan-Mar;6(1):5-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood head and neck cancers are relatively uncommon.
  • Of all head and neck cancers occurring in children, non-Hodgkin's lymphoma (NHL) is the most common, others being rhabdomyosarcoma and nasopharyngeal carcinoma.
  • These can be of several different types depending on the predominant cell type and histologic appearance, the most common histological variant being diffuse large B-cell lymphoma.
  • In an attempt to simplify the classification and to develop a universally acceptable classification and staging, they have been classified and staged numerous times over the last three decades, adding more confusion to the topic.
  • Clinical presentations vary according to the histological type.
  • The low grade lymphomas present with a nasal cavity or para-nasal sinus mass associated with obstructive symptoms and/or lymphadenopathy, while high grade lymphomas present with aggressive signs and symptoms including non-healing ulcer, epistaxis, septal perforation and bony destruction.
  • The primary treatment consists of chemotherapy and / or radiation therapy, which is able to achieve remission in two-third of the patients, however, prognosis remains poor with cumulative five-year survival rates at about 30% for all the types of sino-nasal NHLs.
  • Newer targeted therapy (monoclonal antibodies) and combination therapies (including stem cells) are currently being tested in order to improve survival rates in these patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Nose Neoplasms / pathology. Paranasal Sinus Diseases / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Staging. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479539.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


Advertisement
4. Dulguerov P, Allal AS: Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):67-72
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal and paranasal sinus carcinoma: how can we continue to make progress?
  • PURPOSE OF REVIEW: New developments in the nasal and paranasal sinus cancers are reviewed.
  • RECENT FINDINGS: In addition to woodworking, several risk factors for nasal and paranasal sinus cancers have been identified, most notably smoking.
  • Progress in the differential diagnosis of small round cell nasal and paranasal sinus cancers allows the precise diagnosis of esthesioneuroblastoma.
  • An association of surgery and radiation therapy remains the best treatment modality.
  • Major developments include endoscopic resection of nasal and paranasal sinus cancers, high-precision radiotherapy techniques such as intensity-modulated radiotherapy, and proton-beam radiotherapy.
  • There is probably no role for chemotherapy in esthesioneuroblastoma.
  • Although chemotherapy is important for aggressive neoplasms, its generalized use for nasal and paranasal sinus cancers awaits the application/development of newer drugs.
  • These drugs might be applied locally since the majority of recurrences remain local.
  • SUMMARY: Progress in the treatment of nasal and paranasal sinus cancers could be achieved through better prevention and the developments of more selective treatments such as endoscopic resection, high-precision radiotherapy, and new chemotherapy drugs.
  • [MeSH-major] Carcinoma. Nasal Cavity / pathology. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552261.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


5. Yokoyama J: [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2302-6
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers].
  • Eighteen N3 cases, fourteen skullbase invasion cases and twenty-six cases of paranasal sinus cancer with orbital invasion were treated by superselective intra-arterial chemotherapy using CDDP and sodium thiosulfate to preserve the organs and to improve poor prognosis.
  • CT-arteriography (CTA) was used to diagnosis all feeding arteries of advanced cancers before infusing CDDP.
  • In three cases with extirpation of the eyeball CTA was not used in the treatment, and CDDP was infused into only the maxillary artery excluding the transverse facial artery.
  • Ten cases with superselective intra-arterial chemotherapy originating from only the external carotid artery were significantly better responders than four cases originating from both carotid arteries.
  • CTA is a very efficient method for diagnosing all feeding arteries of advanced cancers in the superselective intra-arterial chemotherapy.
  • [MeSH-major] Angiography. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography. Infusions, Intra-Arterial / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Orbital Neoplasms. Paranasal Sinus Neoplasms / drug therapy. Skull Base Neoplasms / drug therapy. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484060.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Thiosulfates; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Lalami Y, Vereecken P, Dequanter D, Lothaire P, Awada A: Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors. Curr Opin Oncol; 2006 May;18(3):258-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors.
  • PURPOSE OF REVIEW: This is a review about recent clinical developments in rare cancers of the head and neck.
  • RECENT FINDINGS: Progress in molecular biology techniques has allowed the identification of new prognostic factors, and potential molecular-targeted therapies.
  • This is of importance since chemotherapy continues to play a role but is still limited in this group of malignancies.
  • Surgery continues to be the cornerstone of treatment, with a growing interest in the technique of sentinel lymph node biopsy.
  • SUMMARY: As salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck are rare malignancies, these tumors must be treated in specialized anticancer centers with access to the latest surgical and irradiation techniques.
  • Moreover, clinical studies with translational research are needed to identify strong prognostic and predictive factors, and effective molecular-targeted therapies.
  • [MeSH-major] Carcinoma / therapy. Head and Neck Neoplasms / therapy. Melanoma / therapy. Paranasal Sinus Neoplasms / therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blindness / etiology. Clinical Trials as Topic. Combined Modality Therapy. Drug Delivery Systems. Drugs, Investigational / therapeutic use. Humans. Lymphatic Metastasis. Multicenter Studies as Topic. Neoadjuvant Therapy. Palliative Care. Radiation Injuries / etiology. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552238.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 85
  •  go-up   go-down


7. Abrahão M, Gonçalves AP, Yamashita R, Dedivitis RA, Santos RO, Nascimento LA, Mudo ML, Ferraz FA, Cervantes O: Frontal sinus adenocarcinoma. Sao Paulo Med J; 2000 Jul 6;118(4):118-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal sinus adenocarcinoma.
  • CONTEXT: Paranasal sinus cancer is considered rare, with an incidence of less than 1 per 100,000 per year, with the frontal sinus being the primary site in only 0.3%.
  • We report a case of adenocarcinoma arising in the frontal sinus.
  • CT scan showed a soft-tissue mass involving frontal sinus with intracranial invasion through the posterior wall.
  • The anterior ethmoid sinus and the medial aspect of the right orbit were also involved.
  • After surgery she had tumor recurrence, and chemotherapy and radiotherapy were started resulting in partial improvement.
  • [MeSH-major] Adenocarcinoma / diagnosis. Frontal Sinus. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887389.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] BRAZIL
  •  go-up   go-down


8. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • And the imaging studies should include the field of the orbit, sinus, and brain to search for the primary lesions.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Rhabdomyosarcoma / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


9. Vieillot S, Boisselier P, Aillères N, Hay MH, Dubois JB, Azria D, Fenoglietto P: [Paranasal sinus carcinoma]. Cancer Radiother; 2010 Nov;14 Suppl 1:S52-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paranasal sinus carcinoma].
  • [Transliterated title] Cancer des sinus de la face.
  • Cancers of the paranasal sinuses are rare tumors, with treatment based on a multidisciplinary approach.
  • Surgery and radiation therapy, possibly associated with chemotherapy are used to obtain 5 years specific survival rate of 60-70 %.
  • Advances in radiotherapy, including the use of imaging for 3D conformal approach require precise knowledge of the radioanatomy for this type of tumor to determine the different volumes of interest.
  • Purpose of this study was to specify radioanatomy and conformal radiation modalities for cancers of the sinuses, and is illustrated by a case report.
  • [MeSH-major] Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinuses / anatomy & histology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Radiotherapy, Conformal / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21129670.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S: Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol; 2004 Dec 15;22(24):4901-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
  • PURPOSE: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC).
  • PATIENTS AND METHODS: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation.
  • In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P < or = .0001).
  • CONCLUSION: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis.
  • Whether this model is extensible to other head and neck cancers needs appropriate investigation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. DNA Mutational Analysis. Female. Fluorouracil / administration & dosage. Forecasting. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Cantù G, Bimbi G, Fabiani F, Guzzo M, Mattavelli F, Pizzi N, Riccio S, Squadrelli M: [Lymph node metastases in paranasal sinus carcinoma: prognostic value and treatment]. Acta Otorhinolaryngol Ital; 2002 Oct;22(5):273-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymph node metastases in paranasal sinus carcinoma: prognostic value and treatment].
  • The purpose of this report is to assess, on the basis of a sizeable study, the prognostic value of lymph node metastases in paranasal sinus carcinoma and, in particular, in squamous cell carcinoma of the maxillary sinus.
  • We have reviewed the charts of 601 cases of paranasal sinus carcinoma between 1970 and 1999.
  • All of the patients were treated surgically, alone or associated with chemotherapy and/or radiotherapy.
  • The maxillary sinus tumors numbered 379 (153 squamous cell carcinomas, 15 undifferentiated carcinomas, 94 adenoid cystic carcinomas, 19 adenocarcinomas, 98 mesenchymal tumors and rare forms) and the ethmoidal tumors were 222 (117 adenocarcinomas, 27 squamous cell carcinomas, 16 adenoid cystic carcinomas, 13 undifferentiated carcinomas, 49 other histological forms).
  • Lymph node metastases in ethmoidal tumors were rare, with the exception of undifferentiated carcinoma (46.1%).
  • The percentages of metastatic squamous cell carcinoma of the maxillary sinus upon presentation were: T2 15.5%, T3 7%, and T4 4%.
  • The metastases successive to treatment of the primary tumor were: T2 16.9%, T3 8.8%, and T4 12%.
  • 75% of these late metastases occurred contemporaneously with a recurrence of T and only 5 (25%) constituted the single reawakening of disease; four of these patients underwent neck surgery and were cured operatively.
  • The NED survival rate at least two years after T therapy in patients free from metastases was 50.4%, against 25% in those with initial or distant metastases (T2 72.9% vs. 30.4%, T3 37.5% vs. 22.2%, and T4 28.6% vs. 0%).
  • In conclusion, squamous cell carcinomas of the maxillary sinus which have extended to the oral cavity (T2) show greater lymph node propagation than those of the superoposterior portion (T3-T4).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Maxillary Sinus / radiation effects. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12510338.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):27-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
  • PURPOSE: To determine the contribution of debulking surgery on local control and survival in paranasal sinus tumors.
  • METHODS AND MATERIALS: Between 1977 and 1996, 73 patients (50 male: 23 female) with a paranasal sinus carcinoma were treated.
  • The histology distribution was as follows: squamous cell carcinoma, 55%; adenocarcinoma, 19%; adenoid cystic carcinoma, 11%; and undifferentiated carcinoma, 15%.
  • Treatment consisted of surgery only in 3, chemotherapy only in 1, radiotherapy only in 18, both surgery and radiotherapy in 50 patients.
  • One patient did not receive any treatment at all.
  • Three patients had concurrent chemotherapy.
  • However, combination treatment gave significantly better 5-year overall survival (OS) (60% vs. 9%; p = 0.001) and 5-year disease-free survival (DFS) (53% vs. 6%; p < 0. 0001).
  • Cox-regression analysis showed that pathologic N status (p = 0.04), palliative intention of treatment (p = 0.018), clinical orbital invasion (p = 0.003), and orbital wall invasion (p = 0.003) were parameters significantly associated with poor local control.
  • Total radiation dose of greater than 65 Gy (p = 0.05) and treatment consisting of radiotherapy alone (p = 0.002) were associated with worse overall survival; for disease-free survival clinical orbital invasion (p = 0.0005), age of greater than 65 years (p = 0.013) and pathologic T4 classification (p = 0.002) were significant factors for an unfavorable outcome.
  • In 19 of 73 patients, 26 serious (mainly ophthalmological) complications were reported; in the majority of these, the visual tract was (partly) included in the treatment fields because of tumor extension.
  • To analyze on which basis patients were selected for the combination therapy, a logistic regression was performed, concluding that clinical T4 classification (p = 0.05), radiological evidence of skull base invasion (p = 0.005), age of greater than 65 years (p = 0.026), radiological evidence of nasopharynx invasion (p = 0.02), clinical suspicion of palate invasion (p = 0.02), and radiological evidence of skin invasion (p = 0.009) were associated with choosing radiotherapy alone.
  • CONCLUSION: Debulking surgery of paranasal sinus malignancies followed by high-dose radiotherapy to the involved sites was associated with better survival and (although not statistically significant) local control.
  • We favor this combination regimen because the surgery gives quick relief of complaints and, at the same time, offers an excellent histologically proven staging method, enabling radiotherapy to be adjusted to the involved sites, thereby decreasing the risk of complications.
  • [MeSH-major] Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Radiation Injuries / therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924968.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Huang D, Xia P, Akazawa P, Akazawa C, Quivey JM, Verhey LJ, Kaplan M, Lee N: Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):158-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma.
  • PURPOSE: To compare intensity-modulated radiotherapy (IMRT) treatment planning with three-dimensional conformal radiotherapy (3D-CRT) planning for paranasal sinus carcinoma.
  • MATERIALS AND METHODS: Treatment plans using traditional 3-field technique, 3D-CRT planning, and inverse planning IMRT were developed for a case of paranasal sinus cancer requiring adjuvant radiotherapy.
  • Plans were compared with respect to dose conformality, dose-volume histograms, doses to critical normal tissues, and ease of treatment delivery.
  • The dose-volume histograms demonstrated significantly better critical normal-tissue sparing with the IMRT plans, while able to deliver a minimum dose of 60 Gy to the clinical tumor volume and 70 Gy to the gross tumor volume.
  • CONCLUSIONS: IMRT planning provided improved tumor target coverage when compared to 3D-CRT treatment planning.
  • There was significant sparing of optic structures and other normal tissues, including the brainstem.
  • Inverse planning IMRT provided the best treatment for all paranasal sinus carcinomas, but required stringent immobilization criteria.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Adjuvant / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Brain Stem / injuries. Brain Stem / radiation effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Radiation. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Humans. Immobilization. Masks. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Optic Chiasm / radiation effects. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Padovani L, Pommier P, Clippe S S, Martel-Lafay I, Malet C, Poupart M, Zrounba P, Ceruse P, Desmes S, Carrie C, Montbarbon X, Ginestet C: Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):169-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients.
  • PURPOSE: To assess local control, survival, and clinical and dosimetric prognostic factors in 25 patients with locally advanced maxillary or ethmoid sinus carcinoma treated by three-dimensional conformal radiotherapy (RT).
  • Seven patients received chemotherapy (concomitant with RT in four).
  • The following quality indexes were defined for the 95% and 90% isodoses: tumor conformity index, normal tissue conformity index, and global conformity index.
  • RESULTS: The median radiation dose to the planned treatment volume was 63 Gy, with a minimal dose of 60 Gy, except in 2 patients whose cancer progressed during RT.
  • After a median follow-up of 25 months, 14 local tumor recurrences developed.
  • Two patients died of acute infectious toxicity, and two developed late ipsilateral ocular toxicity.
  • CONCLUSIONS: Improving local control remains the main challenge in RT for paranasal tumors.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Ethmoid Sinus. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Follow-Up Studies. Humans. Life Tables. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694835.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Diaz EM Jr, Kies MS: Chemotherapy for skull base cancers. Otolaryngol Clin North Am; 2001 Dec;34(6):1079-85, viii

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for skull base cancers.
  • This article focuses on treatment options for select skull base problems that have decreased post-treatment morbidity and, in many cases, improved survival.
  • The select skull base cancers covered include nasopharyngeal carcinoma, squamous cell carcinoma of the paranasal sinuses, sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, esthesioneuroblastoma, and salivary gland carcinoma.
  • [MeSH-major] Skull Base Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Squamous Cell / drug therapy. Esthesioneuroblastoma, Olfactory / drug therapy. Humans. Paranasal Sinus Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11728933.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


16. Samant S, Kruger E: Cancer of the paranasal sinuses. Curr Oncol Rep; 2007 Mar;9(2):147-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the paranasal sinuses.
  • Carcinoma of the paranasal sinuses is a heterogeneous disease that is frequently locally advanced at presentation.
  • Treatment commonly includes radical surgery followed by adjuvant therapy.
  • Despite such aggressive therapy, the likelihood of locoregional failure is significant, resulting in poor survival, particularly with advanced tumors.
  • In this paper, we review the recent literature in search of advances in treatment optimization.
  • These advances include conformal radiotherapy techniques, chemotherapy, image-guided and endoscopic surgery, and surgical approaches for orbital preservation, all of which have a potential to improve the oncologic outcome as well as cosmetic and functional results.
  • We also outline our approach in using these advances in the management of patients with these cancers.
  • [MeSH-major] Paranasal Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Dec;38(6):1279-99, x [16326185.001]
  • [Cites] Am J Rhinol. 2005 Sep-Oct;19(5):521-8 [16270609.001]
  • [Cites] Am J Clin Oncol. 2005 Oct;28(5):474-8 [16199987.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):856-64 [15708266.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Indian J Cancer. 2006 Jan-Mar;43(1):26-9 [16763359.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):51-8 [15093898.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Dec;131(6):973-6 [15577800.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Aug;24(4):199-203 [15688904.001]
  • [Cites] Laryngoscope. 2005 Nov;115(11):1983-7 [16319610.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):67-75 [15803378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):776-84 [12573765.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1357-65 [12172245.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Head Neck. 2005 Jul;27(7):575-84 [15825201.001]
  • (PMID = 17288882.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


17. Blanco AI, Chao KS, Ozyigit G, Adli M, Thorstad WL, Simpson JR, Spector GJ, Haughey B, Perez CA: Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys; 2004 May 1;59(1):51-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy.
  • PURPOSE: To assess the clinical features, prognostic factors, results, and complications of treatment of carcinomas of the paranasal sinus.
  • METHODS AND MATERIALS: The records of 106 patients (72 men and 34 women) with paranasal sinus carcinoma treated with curative intent at Washington University between January 1960 and August 1998 were analyzed.
  • Most tumors originated in the maxillary (76%) or ethmoid (18%) sinus.
  • All patients underwent radiotherapy (RT), combined with surgery in 65%; 2% received chemotherapy.
  • CONCLUSION: This review of a large, single-institution experience of paranasal sinus carcinoma patients who underwent RT showed that locoregional tumor progression and recurrence remain predominant patterns of failure despite aggressive local treatment with combined surgery and RT.
  • DFS improved slightly with combined modality treatment.
  • The overall survival rates remained suboptimal, suggesting a need for more accurate determination of tumor extent, as well as more effective locoregional and systemic therapies.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Prognosis. Proportional Hazards Models. Radiation Injuries / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15093898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. DeMonte F, Ginsberg LE, Clayman GL: Primary malignant tumors of the sphenoidal sinus. Neurosurgery; 2000 May;46(5):1084-91; discussion 1091-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant tumors of the sphenoidal sinus.
  • OBJECTIVE: Neoplasms of the paranasal sinuses account for 0.2 to 0.8% of all cancers and for 2 to 3% of head and neck cancers.
  • Primary involvement of the sphenoidal sinus has been reported to occur in only 1 to 2% of all paranasal sinus tumors.
  • Tumors at this site commonly present with cranial neuropathies and require multidisciplinary treatment.
  • METHODS: During a 21-year period, 27 patients with primary sphenoidal sinus tumors were evaluated.
  • The records of all remaining patients were reviewed for the following parameters: age, sex, and ethnic origin; presenting symptoms and signs; radiological features and sites of tumor extension; pathological findings; prior treatments; surgical approaches and extent of resection; adjuvant therapy; complications; and patient outcome.
  • The most common diseases were squamous cell carcinoma (n = 9), adenoid cystic carcinoma (n = 4), chondrosarcoma (n = 3), and neuroendocrine carcinoma (n = 3).
  • Treatments included surgery (n = 1), surgery and radiotherapy (n = 6), surgery and chemotherapy (n = 3), surgery, radiotherapy, and chemotherapy (n = 4), chemotherapy (n = 5), chemotherapy and radiotherapy (n = 3), and radiotherapy (n = 2).
  • The 2-year survival rate for patients with squamous cell carcinoma was 44%.
  • CONCLUSION: Headache and visual disturbances are common symptoms of sphenoidal sinus tumors.
  • It is advantageous if the surgical team has had experience with both open and endoscopic approaches to the sphenoidal sinus.
  • Patient outcome is maximized by the use of aggressive multidisciplinary therapy.
  • [MeSH-major] Paranasal Sinus Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Chondrosarcoma / diagnosis. Chondrosarcoma / mortality. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Combined Modality Therapy. Endoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807240.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Yigit O, Taskin U, Demir A, Behzatoglu K: Incidentally diagnosed simultaneous second primary tumor of the sphenoid sinus in a patient with lung cancer. J Craniofac Surg; 2009 Nov;20(6):2175-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidentally diagnosed simultaneous second primary tumor of the sphenoid sinus in a patient with lung cancer.
  • Synchronous tumors are described as multiple primary malignancies presenting within 6 months of diagnosis of index tumors.
  • However, isolated sphenoid sinus and lung cancers are not reported yet.
  • Here, we reported an incidentally diagnosed simultaneous second primary sphenoid sinus tumor in a patient with lung cancer.
  • Radiological evaluation results demonstrated a significant contrast-enhanced mass in the sphenoid sinus extending through the nasopharynx because of the destruction of the sphenoid sinus.
  • The decision was made to proceed with chemotherapy and radiotherapy treatment regimens for the sphenoid sinus lesion, and right lobectomy was performed for the lung lesion.
  • Asymptomatic simultaneous, synchronous, or metastatic tumors must always be kept in mind, and histopathologic diagnosis should be done for both tumors because presence of second tumor anywhere may change the treatment modality.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Paranasal Sinus Neoplasms / pathology. Sphenoid Sinus / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Sinus cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884834.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


20. Kiprian D: [Strategy of combined treatment in patient with cancer of paranasal sinuses]. Otolaryngol Pol; 2007;61(4):527-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy of combined treatment in patient with cancer of paranasal sinuses].
  • Cancers of pranasal sinuses are rare neoplasms in humans.
  • Squamous cell cancer is the most frequent one in this region.
  • Other types of cancer in this region are adenocarcinoma (about 30%), carcinoma adenoides cysticum or neoplasms such as rhabdosarcoma, chondrosarcoma, lymphoma or melanoma malignum.
  • Cancer of the paranasal sinuses infiltrates only locoregionally.
  • Metastases to the lymph nodes are seldom--below 30%; this is why elective lymphangiectomy or irradiation are not obligatory treatment in this case.
  • The treatment of cancers of paranasal sinuses is always surgery with adjuvant irradiation.
  • The modern radiotherapy techniques provide the possibility to spare healthy tissues and organs at risk.
  • The radiation treatment combined with chemotherapy is applied in cases of not radical surgery in the region of ethmoides sinuses.
  • [MeSH-major] Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Incidence. Neoplasm Staging. Radiotherapy, Conformal. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260245.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 5
  •  go-up   go-down


21. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • A wide variety of histologies may be encountered, although squamous cell carcinoma (SCCA) is the most common.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


22. Lin CY, Chen HH, Chen HH, Fang SY, Tsai ST: Ethmoid sinus cancer: results of treatment with surgery and combined therapy. Acta Otolaryngol; 2004 Dec;124(10):1220-5
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethmoid sinus cancer: results of treatment with surgery and combined therapy.
  • OBJECTIVE: Ethmoid sinus cancer is a rare paranasal sinus malignancy.
  • Its characteristics include a low incidence rate, a great variety of histopathological types and multiple treatment modalities.
  • The aim of this study was to examine the outcome of a population of Asian patients with advanced ethmoid sinus cancers that had been treated with surgery plus combined therapy.
  • MATERIAL AND METHODS: Between January 1989 and December 2002 inclusive, 19 newly diagnosed patients with ethmoid sinus cancers who had undergone surgical intervention were enrolled, T4 being the principal carcinoma stage (68.4%).
  • All participating cases proved to be node-negative and no evidence of any distant metastasis was detected at the time of diagnosis.
  • The major treatment modality was surgery plus postoperative radiotherapy.
  • All but 2 of the 13 patients with T4 cancer underwent craniofacial resection with pericranial flap reconstruction.
  • RESULTS: The estimated overall and disease-free survival rates 3 years post-treatment were 49.4% and 26.3%, respectively.
  • A total of 5/15 T3-T4 patients (33%) developed a neck metastasis, 3 of whom also suffered a distant metastasis.
  • CONCLUSIONS: Ethmoid sinus cancer typically demonstrates a propensity for late diagnosis and poor prognosis.
  • This study confirms that craniofacial resection plus combined associated therapy is the optimal approach for the effective management of extensive ethmoid sinus tumors and is associated with an acceptable morbidity rate.
  • More aggressive disease management featuring prophylactic concurrent chemoradiotherapy including neck or elective neck dissection plus chemotherapy should be considered for T3-T4 patients as opposed to T1-T2 patients.
  • [MeSH-major] Carcinoma / therapy. Ethmoid Sinus. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768822.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


23. McKay SP, Shibuya TY, Armstrong WB, Wong HS, Panossian AM, Ager J, Mathog RH: Cell carcinoma of the paranasal sinuses and skull base. Am J Otolaryngol; 2007 Sep-Oct;28(5):294-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell carcinoma of the paranasal sinuses and skull base.
  • PURPOSE: To evaluate patients with squamous cell carcinoma of the paranasal sinus and skull base for factors that might predict clinical outcome.
  • RESULTS: Of 73 patients with anterior skull base malignancies, squamous cell carcinoma was the most prevalent-30 patients or 41%.
  • Twenty-three patients underwent craniofacial surgery with or without adjuvant chemotherapy.
  • Seven patients, deemed unresectable or not willing to have surgery, were treated with standard radiation protocols often with chemotherapy.
  • Although 3- and 5-year survival of tumors free of sphenoid sinus, dura, retromaxillary, and ptyerygoid space, and orbit treated with surgery showed no significant difference to those patients with involvement, their median time of survival was increased for all anatomical regions.
  • CONCLUSIONS: Squamous cell carcinoma of the sinus invading the skull base carries a very poor prognosis regardless of treatment modality.
  • Surgery with adjunctive radiotherapy and/or chemotherapy offers a survival advantage over nonsurgical methods, but treatment should be individualized weighing prognostic factors, such as age, stage, and anatomical extension with morbidity of treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Paranasal Sinus Neoplasms / therapy. Skull Base Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prevalence. Proportional Hazards Models. Quality of Life. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826529.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, Pfister DG, Zelefsky MJ, Shah JP, Kraus DH, Lee NY: Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):763-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities.
  • PURPOSE: To evaluate long-term outcomes and toxicity in patients with unresectable paranasal sinus carcinoma treated with radiotherapy, with or without chemotherapy.
  • METHODS AND MATERIALS: Between January 1990 and December 2006, 39 patients with unresectable Stage IVB paranasal sinus carcinoma were treated definitively with chemotherapy plus radiotherapy (n = 35, 90%) or with radiotherapy alone (n = 4, 10%).
  • Patients were treated with three-dimensional conformal radiotherapy (n = 18, 46%), intensity-modulated radiotherapy (n = 12, 31%), or conventional radiotherapy (n = 9, 23%) to a median treatment dose of 70 Gy.
  • Most patients received concurrent platinum-based chemotherapy (n = 32, 82%) and/or concomitant boost radiotherapy (n = 29, 74%).
  • Nine patients developed neck relapses; however none of the 4 patients receiving elective neck irradiation had a nodal relapse.
  • In 13 patients acute Grade 3 mucositis developed.
  • Severe late toxicities occurred in 2 patients with radionecrosis and 1 patient with unilateral blindness 7 years after intensity-modulated radiation therapy (77 Gy to the optic nerve).
  • The only significant factor for improved local progression-free survival and overall survival was a biologically equivalent dose of radiation >/=65 Gy.
  • CONCLUSIONS: Treatment outcomes for unresectable paranasal sinus carcinoma are poor, and combined-modality treatment is needed that is both more effective and associated with less morbidity.
  • [MeSH-major] Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Patient Selection. Platinum Compounds / therapeutic use. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Radiotherapy, Intensity-Modulated / methods. Survival Analysis. Survivors. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395361.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds
  •  go-up   go-down


25. Samant S, Robbins KT, Vang M, Wan J, Robertson J: Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg; 2004 Aug;130(8):948-55
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer.
  • OBJECTIVE: To report the long-term efficacy of a combined regimen of intra-arterial high-dose cisplatin chemotherapy and concomitant radiation therapy followed by organ-sparing surgery when possible in the treatment of advanced paranasal sinus cancer.
  • Patients Nineteen patients with advanced paranasal sinus malignancies with a minimum follow-up of 2 years.
  • Malignancies included 14 squamous cell carcinomas (74%), 2 adenocarcinomas (10%), 2 adenoid cystic carcinomas (10%), and 1 undifferentiated carcinoma (5%).
  • Intervention Treatment consisted of preoperative radiation therapy (2.0 Gy/fraction per day; total dose, 50 Gy in 5 weeks) given concomitantly with 3 to 4 weekly infusions of intra-arterial cisplatin (150 mg/m(2) per week) and systemic sodium thiosulfate neutralization.
  • The regimen included planned surgery performed approximately 8 weeks after completion of radiation therapy.
  • One patient died of myocardial infarction during treatment.
  • No other treatment-limiting toxic effect was noted.
  • Except for cataract in 2 patients, no visual loss developed.
  • CONCLUSION: Despite the advanced stage and unfavorable nature of cancer in this cohort, our results indicate that this regimen holds promise and merits further study.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Maxillary Sinus / pathology. Maxillary Sinus / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Computer-Assisted. Surgical Procedures, Operative
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / mortality. Prospective Studies. Radiation Dosage. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313865.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, Yoon JH: Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol; 2005 Feb;125(2):201-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulindac sulfide-induced apoptosis in sinonasal cancer cells.
  • CONCLUSIONS: These results demonstrate that sulindac sulfide can induce cell death in maxillary cancer cells, and that sulindac sulfide-induced apoptosis is related to the extracellular signal-regulated kinase/p38 MAPK-caspase 3 signaling pathway.
  • OBJECTIVE: Head and neck cancer is the sixth commonest cancer in the human body.
  • Squamous cell carcinoma accounts for most sinonasal cancers.
  • However, little is known regarding the biochemical mechanism(s) of cell death in sinonasal cancers.
  • Recently, human epidemiological and clinical intervention studies have indicated that sulindac, a non-steroidal anti-inflammatory drug, exhibits chemopreventive activity in colorectal cancer.
  • In this study, we aimed to investigate whether sulindac sulfide can induce apoptosis in sinonasal cancer cells and what type of molecular mechanisms induces the death of sinonasal cancer cells.
  • MATERIAL AND METHODS: Sinonasal cancer cells (Asan Medical Center Head and Neck Cancer 5) were treated with various concentrations of sulindac sulfide.
  • RESULTS: Human nasal cavity cancer cells treated with sulindac sulfide underwent cell death, and the induction of apoptosis occurred in a dose-dependent manner.
  • Moreover, sulindac sulfide-induced apoptosis was abolished by treatment with the caspase inhibitor Z-VAD-fmk and the mitogen-activated protein kinase (MAPK) inhibitors PD98059 and SB203580.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Apoptosis / drug effects. Carcinoma, Squamous Cell / drug therapy. Paranasal Sinus Neoplasms / drug therapy. Sulindac / analogs & derivatives. Sulindac / pharmacology. Sulindac / therapeutic use
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / administration & dosage. Amino Acid Chloromethyl Ketones / pharmacology. Caspase Inhibitors. Flavonoids / administration & dosage. Flavonoids / pharmacology. Fluorescence. Humans. Imidazoles / administration & dosage. Imidazoles / pharmacology. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Pyridines / administration & dosage. Pyridines / pharmacology. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880954.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Amino Acid Chloromethyl Ketones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Caspase Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


27. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thöni A, Ozsahin M, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C: Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol; 2004 Dec 1;22(23):4665-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
  • PATIENTS AND METHODS: From July 1994 to July 2000, 224 patients with squamous cell carcinomas of the head and neck (excluding nasopharynx and paranasal sinus) were randomly assigned to hyperfractionated radiotherapy (median dose, 74.4 Gy; 1.2 Gy twice daily) or the same radiotherapy combined with two cycles of concomitant cisplatin (20 mg/m2 on 5 days of weeks 1 and 5).
  • The primary end point was time to any treatment failure; secondary end points were locoregional failure, metastatic relapse, overall survival, and late toxicity.
  • RESULTS: There was no difference in radiotherapy between both treatment arms (74.4 Gy in 44 days).
  • The full cisplatin dose was applied in 93% and 71% of patients during the first and second treatment cycles, respectively.
  • Median time to any treatment failure was not significantly different between treatment arms (19 months for combined treatment and 16 months for radiotherapy only, respectively) and the failure-free rate at 2.5 years was 45% and 33%, respectively.
  • Late toxicity was comparable in both treatment groups.
  • CONCLUSION: The therapeutic index of hyperfractionated radiotherapy is improved by concomitant cisplatin.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reference Values. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Switzerland. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Dec 1;22(23):4657-9 [15534361.001]
  • [ErratumIn] J Clin Oncol. 2005 Jan 1;23(1):248
  • (PMID = 15534360.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results.
  • OBJECTIVE: To evaluate the oncologic outcomes of patients with sinonasal cancer treated with endoscopic resection.
  • SETTING: Tertiary care academic cancer center.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Other, less common tumors included adenoid cystic carcinoma (7%), neuroendocrine carcinoma (4%), and sinonasal undifferentiated carcinoma (2%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Guillotte-van Gorkum ML, Nasser T, Mérol JC, Legros M, Rousseaux P, Chays A: [Ethmoid adenocarcinoma: a series of 17 cases]. Ann Otolaryngol Chir Cervicofac; 2003 Nov;120(5):296-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Adénocarcinomes de l'ethmoïde. Notre expérience à propos d'une série de 17 cas.
  • INTRODUCTION: Ethmoid adenocarcinoma are and represent rare, 2.5 to 3% of head and neck cancers.
  • OBJECTIVES: Expose the treatment of these patients and evaluate the results.
  • Most teams agree that postoperative radiotherapy is necessary but the appropriateness of chemotherapy is still discussed.
  • [MeSH-major] Adenocarcinoma / therapy. Ethmoid Sinus. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14726849.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


30. Airoldi M, Garzaro M, Valente G, Mamo C, Bena A, Giordano C, Pecorari G, Gabriele P, Gabriele AM, Beatrice F: Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology; 2009;76(4):262-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region.
  • OBJECTIVES: In spite of aggressive surgery and high-dose radiotherapy, the long-term survival of patients with sinonasal cancer remains disappointing.
  • Patients with T1-T2 adenocarcinoma and squamous cell cancers (SCC) had better median survival than those with other lesions (p < 0.05).
  • Patients treated with surgery with or without radiotherapy had better survival (p < 0.01), while chemotherapy had a marginally favorable effect (p = 0.09).
  • The type of surgery and radiotherapy dose had no impact on survival; in contrast, there was a strong association between Ki-67 expression and microvessel density and overall survival (p < 0.05 and p = 0.039, respectively), while VEGF-C was a prognostic factor in SCC patients only (p < 0.05).
  • CONCLUSIONS: In sinonasal cancer, tumor stage and histology have a clear impact on survival; surgery with or without radiotherapy represents the main choice of treatment for such tumors.
  • The proliferative index and angiogenesis show a major role in the natural history of this cancer.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vascular Endothelial Growth Factor C / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19258726.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


31. Kin S, Wanibuchi M, Minamida Y, Yamaki T, Tanabe S, Houkin K: [A case of sinonasal carcinoma with intracranial invasion treated by a multidisciplinary team]. No Shinkei Geka; 2003 Jun;31(6):677-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sinonasal carcinoma with intracranial invasion treated by a multidisciplinary team].
  • We report a case of a 66-year-old male with diffuse infiltration of neoplasm from the paranasal sinuses to the orbit and left cerebral hemisphere, associated with prominent edema.
  • Neuroimaging showed marked invasion of a neoplasm from the left paranasal sinuses into the intracranial space and to the frontal skull.
  • The pathological diagnosis was "poorly differentiated carcinoma from the paranasal sinus".
  • Postoperatively the patient received radiation and chemotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Small Cell / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Neoplasm Invasiveness. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12833878.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. DeLaney TF: Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. Technol Cancer Res Treat; 2007 Aug;6(4 Suppl):61-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center.
  • The Francis H. Burr Proton Therapy Center has a 230 MeV cyclotron from which proton beams are directed to two isocentric gantries, a stereotactic intracranial beam line, and an eye line.
  • The improved dose localization also reduces normal-tissue doses with an anticipated reduction in acute and late toxicity.
  • Clinical treatment protocols, developed to exploit the dosimetric advantages of protons over photons, have been grouped into two broad categories.
  • In the second, normal-tissue sparing with protons is designed to minimize acute and late toxicity.
  • Treatment of patients on clinical research protocols has been encouraged.
  • Patient treatments began on the first gantry in November 2001; on the eye line in April 2002; on the second gantry in May 2002; and on the stereotactic intracranial line in August 2006.
  • Dose-escalation studies have been completed for early stage prostate cancer (in conjunction with Loma Linda University) and sarcomas of the cervical spine/base of skull and thoracolumbosacral spine.
  • Protocols are in progress or development for carcinoma of the nasopharynx, paranasal sinus carcinoma, non-small-cell lung carcinoma, locally advanced carcinoma of the prostate, hepatocellular carcinoma, and pancreatic cancer.
  • Studies evaluating the use of protons for morbidity reduction include protocols for craniospinal irradiation in conjunction with systemic chemotherapy for medulloblastoma, retinoblastoma, pediatric rhabdomyosarcoma, other pediatric sarcomas, and accelerated, hypofractionated partial breast irradiation for T1N0 breast carcinomas.
  • Treatment of patients on these studies has often required the development of new treatment techniques (i.e., matching abutting fields for craniospinal irradiation), respiratory gating, and development of appropriate clinical infrastructure support (i.e., increase in availability of pediatric anesthesia) to allow appropriate treatment.
  • Results to date indicate that proton radiation therapy offers several potential treatment advantages to patients that can be studied in the setting of clinical trials.
  • [MeSH-major] Cyclotrons. Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668954.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


33. Garrott H, O'Day J: Optic neuropathy secondary to radiotherapy for nasal melanoma. Clin Exp Ophthalmol; 2004 Jun;32(3):330-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optic neuropathy is a rare but important complication of radiotherapy used in the treatment of cancers of the head and neck, usually resulting in rapidly progressive blindness in one or both eyes.
  • Despite treatment with oral anticoagulation and high dose intravenous methylprednisolone, there was progressive deterioration resulting in bilateral optic atrophy, with final visual acuities of perception of light in the right eye and no perception of light in the left eye.
  • This case demonstrates that oral anticoagulation was ineffective in the treatment of progressive radiation-induced optic neuropathy.
  • [MeSH-major] Melanoma / radiotherapy. Optic Nerve / radiation effects. Optic Nerve Diseases / etiology. Paranasal Sinus Neoplasms / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Aged. Anticoagulants / therapeutic use. Drug Therapy, Combination. Female. Glucocorticoids / therapeutic use. Humans. Magnetic Resonance Imaging. Methylprednisolone / therapeutic use. Radiotherapy / adverse effects. Visual Fields. Warfarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Ophthalmol. 2004 Jun;32(3):233-5 [15180831.001]
  • (PMID = 15180849.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Glucocorticoids; 5Q7ZVV76EI / Warfarin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


34. Meyers CA, Geara F, Wong PF, Morrison WH: Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys; 2000 Jan 1;46(1):51-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive effects of therapeutic irradiation for base of skull tumors.
  • PURPOSE: To determine whether radiation therapy delivered to the paranasal sinuses causes any long-term impairment in neurocognitive function as a result of incidental brain irradiation.
  • METHODS AND MATERIALS: Nineteen patients who received paranasal sinus irradiation at least 20 months and up to 20 years before assessment were given a battery of neuropsychologic tests of cognitive function.
  • The median radiation dose was 60 Gy (range 50-68 Gy) in fractions of 1.8 to 2 Gy.
  • The volume of irradiated brain was calculated from planning computed tomography slices or simulation films.
  • Three patients also developed pituitary dysfunction.
  • Neurocognitive symptoms were related to the total dose of radiation delivered but not to the volume of brain irradiated, side of radiation boost, or chemotherapy treatment.
  • CONCLUSIONS: Radiation therapy for paranasal sinus cancer may cause delayed neurocognitive side effects.
  • [MeSH-minor] Adult. Aged. Ethmoid Sinus. Female. Humans. Magnetic Resonance Imaging. Male. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Neuropsychological Tests. Paranasal Sinus Neoplasms / radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10656372.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement